Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo's Majority Stake In Ranbaxy Will Increase Production Capacity In India, Expand Global Footprint In Developing Markets – Japanese Analysts

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Daiichi Sankyo will make a foray into the generics business with its Ranbaxy acquisition, and will shift much of its domestic production to Ranbaxy to save costs, analysts in Japan said. However, the Japanese company will not sell its brand drugs through Ranbaxy's distribution channels, nor will the two companies start a joint generics business in Japan, they speculated

You may also be interested in...



Daiichi Sankyo To Expand European Presence With Acquisition Of 130 Merck KGaA Medical Reps

TOKYO - Daiichi Sankyo's German subsidiary reached an agreement to acquire approximately 130 primary-care medical representatives now working for Merck Serono in Germany as part of the Japanese company's European business expansion, a Daiichi Sangyo spokesman

Daiichi Sankyo To Expand European Presence With Acquisition Of 130 Merck KGaA Medical Reps

TOKYO - Daiichi Sankyo's German subsidiary reached an agreement to acquire approximately 130 primary-care medical representatives now working for Merck Serono in Germany as part of the Japanese company's European business expansion, a Daiichi Sangyo spokesman

Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs

NEW DELHI - Japan's Daiichi Sankyo will buy a majority stake in India's top drug maker in a deal that will vault the combined operations into the top 15 pharmaceutical firms globally and end the founding Singh family's role as largest shareholder of Ranbaxy Laboratories

Related Content

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel